About ALPCO
ALPCO is a Healthcare company based in Salem (United States) founded in 1991, and was acquired by Ampersand Capital in September 2020. It operates as an immunoassays and reagents for research in medical sectors are provided. Its website alpco.com draws about 23 thousand monthly visits. ALPCO offers products and services including Calprotectin Immunoturbidimetric Assay, ALEX² Allergy Explorer Kit, and Pancreatic Elastase Chemiluminescence ELISA. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Diversified.
Company details
The company was established in 1991 and is based in Salem, United States. Research and clinical immunoassays, flow cytometry reagents, HPLC LCMS reagents, and chemiluminescence reagents are supplied for sectors including antibodies and antigens, allergy and infectious disease, bone metabolism, cardiovascular and oxidative health, diabetes and obesity, endocrinology, gastroenterology, immunology, neurobiology, and toxicology. Clients served include Quest Diagnostics, Covance, UBC, and Jewish General Hospital.
- Investors
- Acquired byAmpersand Capital
(Sep 2020)
Products & Services of ALPCO
ALPCO offers a comprehensive portfolio of products and services, including Calprotectin Immunoturbidimetric Assay, ALEX² Allergy Explorer Kit, and Pancreatic Elastase Chemiluminescence ELISA.
Quantitative test for fecal calprotectin to aid GI disease diagnosis
Measures allergen-specific IgE for allergy assessment
Quantifies pancreatic elastase in stool for enzyme output evaluation
Apps and channels of ALPCO
its YouTube channel ALPCO has 346 subscribers and 30 videos.
Videos from ALPCO
The most watched videos on ALPCO's YouTube channel, ALPCO (346 subscribers). Click a video to play it here.
More on ALPCO.
Investors in ALPCO
ALPCO has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | – | ampersandcapital.com | Boston, United States |
Investor details for ALPCO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ALPCO
14 people are tracked at ALPCO (7 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Chris Wisherd | Vice President, Scientific Operations | Leadership |
Bethany Bell | Vice President Of Global Business Development | Leadership |
Richard Conley | CEO | Leadership |
Elias Elachi | Director Of Operations | Leadership |
Erik Allen | Chief Executive Officer And President | Leadership |
Jim Richard | VP Quality & Regulatory | Leadership |
Ken Titlebaum | CFO | Leadership |
Gustavo Marques | Senior Reagent Chemistry Manufacturing Associate | Team |
Jennifer Petzke Ph. D | Manager, R&d | Team |
Justin Gonsalves | Accounting & Systems Manager | Team |
Julie Melito | Process Scientist | Team |
Brian Kluk | Sr. Technical Support/complaint Specialist | Team |
Ashley Farnsworth | Associate QA Specialist | Team |
Reid Millican | Inside Sales Specialist | Team |
Complete people profiles for ALPCO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ALPCO
2 dated milestones of ALPCO across 29 years, from founding to its latest funding, stage changes and deals.
- Founded ALPCO is founded.
- Exit Acquired by Ampersand Capital.
Web traffic of ALPCO
The website of ALPCO (alpco.com) receives about 22.6K visits a month.
- Monthly visits22.6K
▲ 101.9% vs previous month
Websites whose visitors overlap most with ALPCO. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| abcam.com | 100% | 602.8K | #91,958 | View details | |
| rndsystems.com | 99% | 349K | #159,292 | View details | |
| caymanchem.com | 99% | 393.1K | #148,469 | View details | |
| abnova.com | 98% | 30.7K | #957,320 | View details | |
| crystalchem.com | 97% | 4.5K | #4,393,035 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for ALPCO
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as ALPCO (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alpco
Complete news archive for ALPCO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ALPCO
ALPCO was founded in 1991.
ALPCO is headquartered in Salem, United States.
The company was established in 1991 and is based in Salem, United States. Research and clinical immunoassays, flow cytometry reagents, HPLC LCMS reagents, and chemiluminescence reagents are supplied for sectors including antibodies and antigens, allergy and infectious disease, bone metabolism, cardiovascular and oxidative health, diabetes and obesity, endocrinology, gastroenterology, immunology, neurobiology, and toxicology. Clients served include Quest Diagnostics, Covance, UBC, and Jewish General Hospital.
ALPCO offers Calprotectin Immunoturbidimetric Assay, ALEX² Allergy Explorer Kit, and Pancreatic Elastase Chemiluminescence ELISA.
ALPCO has 1 investor. Key investors include Ampersand Capital Partners.
Yes. ALPCO was acquired by Ampersand Capital in September 2020.